Regulus Therapeutics (NASDAQ:RGLS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Saturday. The brokerage currently has a $2.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 2.56% from the company’s current price.
According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “
Several other research analysts also recently issued reports on the company. Wedbush reaffirmed a “hold” rating and set a $1.00 price objective on shares of Regulus Therapeutics in a report on Friday, August 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a report on Friday, August 10th. ValuEngine raised Regulus Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. B. Riley reduced their price objective on Regulus Therapeutics from $1.00 to $0.50 and set a “neutral” rating on the stock in a report on Friday, July 6th. Finally, Leerink Swann downgraded Regulus Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, July 10th. Eight investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Regulus Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $1.42.
NASDAQ:RGLS opened at $1.95 on Friday. Regulus Therapeutics has a 52-week low of $1.89 and a 52-week high of $17.28. The firm has a market cap of $20.71 million, a price-to-earnings ratio of -2.03 and a beta of 1.38.
Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. Regulus Therapeutics had a negative return on equity of 205.48% and a negative net margin of 83,538.89%. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Equities analysts expect that Regulus Therapeutics will post -0.49 earnings per share for the current year.
An institutional investor recently bought a new position in Regulus Therapeutics stock. A.R.T. Advisors LLC purchased a new stake in Regulus Therapeutics Inc (NASDAQ:RGLS) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 169,416 shares of the biopharmaceutical company’s stock, valued at approximately $121,000. A.R.T. Advisors LLC owned 0.16% of Regulus Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 49.55% of the company’s stock.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Featured Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.